ISTH 2026 Supported Symposia & Presentation Theaters
​

Our Congress program offers several time slots for informing ISTH 2026 participants about the latest research, product developments, and other scientific activities. Supported Symposia are scientific or educational in nature, offering a platform for in-depth presentations and discussions. Meanwhile, Presentation Theaters are designed to provide industry partners with an opportunity to showcase new research findings, share product information, offer live demonstrations, or raise disease awareness among ISTH 2026 Congress delegates. We hope you will take advantage of these valuable opportunities to engage with the global hemostasis and thrombosis community and highlight your latest innovations.​

 

See below for session titles, dates and times.

 

Saturday, July 11, 11:30 – 12:45  |  Supported Symposia​

• ​When Conventional Treatment Is Not Enough: Escalating Care in PE and DVT – A Multidisciplinary Perspective (Inari Medical) 
  Room W07-08

• The ITP Conversation: Today’s Practice, Tomorrow’s Potential (Novartis) 
  Room W01-02

​

Sunday, July 12, 12:15-13:30  |  Supported Symposia

• ​Von Willebrand Disease: A Holistic Approach (CSL)
  Room W01-02

• Starting Strong, Staying Strong: Evidence for Sustained Protection for a Life with Haemophilia A (F. Hoffmann-La Roche Ltd and Chugai Pharmaceutical Co. Ltd)
  Room E04-06

• Closer to Nature. Designed for Protection. Scientific symposium on ULTRA 8, an investigational FVIII in development (Octapharma)
  Room W05-06

• Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes (PeerVoice)
  Room W07-08

• Evolving Clinical Pathways in iTTP: Emerging Treatment Approaches and Managing Complex Cases (Sanofi)
  Room W03-04

• The Future of Hemostasis Rebalancing (Sanofi)
  Room E03-04

 

Sunday, July 12, 13:45 - 14:30  |  Presentation Theaters

• ​HEMGENIX® in Practice: Real-World Strategies and Learnings (CSL)
  Presentation Theater 3​

• The Paediatric VWD Journey: Burden of Disease and Treatment Realities (Takeda)
  Presentation Theater 4

• High-Sensitivity D-Dimer in VTE Exclusion: Clinical Decision Rules and Global Harmonization (Werfen)
  Presentation Theater 2

 

Monday, July 13, 12:15 - 13:30  | Supported Symposia

• Personalised Future: Gene Therapy and Patient-Reported Outcomes in Haemophilia (CSL)
  Room E05-06

• From Evidence to Individualisation: Redefining Prophylaxis in von Willebrand Disease (Octapharma)
  Room W03-04

• Haemophilia Beyond the Basics: From Complex Scenarios to Confident Care (Pfizer)
  Room W07-08

• From Immune Mechanisms to Clinical Practice: Rethinking Autoimmune Cytopenias (Sanofi)
  Room W01-02

• Shaping the Future of Haemophilia A: Redefining Clinical Outcomes (Swedish Orphan Biovitrum (Sobi))
  Room E03-04

• Prophylaxis across the axis: Key considerations for patient care in VWD and cTTP (Takeda)
  Room W05-06

 

Monday, July 13, 13:45 – 14:30  |  Presentation Theaters

• ​A Decade of IDELVION®: From Evidence to Confidence (CSL)
  Room Presentation Theater 3

• Everyday Protection with Alhemo®: Redefining Precision and Control in Haemophilia B (Novo Nordisk Healthcare AG)
  Room Presentation Theater 2

• The Impact of High Sustained Factor Activity: Real-World Insights With ALTUVIIIO® (Sanofi)
  Room Presentation Theater 1

• From HIT IgG to ADAMTS-13 activity: High-Sensitivity Chemiluminescence on a routine coagulation analyzer (Sysmex Europe SE)
  Room Presentation Theater 4

 

Tuesday, July 14, 12:15 – 13:30  |  Supported Symposia

• Clinical Decision Making in Hereditary Factor X Deficiency: Tailoring Care for Women, Girls, and Pediatric Patients (Kedrion Biopharma)
  Room W01-02

• Challenging the status quo: towards better patients' outcomes in VWD (LFB BIOMEDICAMENTS)
  Room W07-08

• From Molecular Mimicry to Patient Mastery: The New Normal? (Novo Nordisk Healthcare AG)
  Room W03-04

• Same Goals, New Paths: Evaluating today’s haemostatic therapies (Octapharma)
  Room E03-04

 

Tuesday, July 14, 13:45 – 14:30  |  Presentation Theater

• ​​​Plasminogen Deficiency Type 1: A Rare Multisystem Disease with Lifelong Clinical Consequences (Kedrion Biopharma)
  Presentation Theater 3

• “Remodelling the perioperative pathway for patients with haemophilia with inhibitors: a case based discussion”- AN INTERACTIVE DEBATE (LFB BIOMEDICAMENTS)
  Presentation Theater 4

 

☆ = Promotional bundle partners​